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Background and objectives
Familial amyloidotic polyneuropathy (FAP) is a fatal,
autosomal dominant disease caused by abnormal tissue
deposition of mutant and wild-type transthyretin (TTR)
in peripheral nerves, gastrointestinal tract, and heart.
Since the liver is the primary source of WT and mutant
TTR, orthotopic liver transplantation (OLT) has been the
standard of care in select patients. Despite undergoing
OLT, some patients experience progression of their
underlying disease. There is evidence to suggest that dis-
ease progression after OLT is caused by ongoing deposi-
tion of WT TTR protein produced by the transplanted
liver. In order to better understand the natural history of
patients receiving FAP-OLT, we performed a retrospec-
tive assessment of time to polyneuropathy disability
(PND) score progression.
Methods
We characterized neuropathy severity with the (PND)
score. Descriptive statistics including proportions of
FAP patients who progress by at least one PND stage
after OLT and median time to PND stage progression
were assessed in available FAP-OLT patients in Sweden,
Portugal, Spain, Italy and France from 1991-2015. The
Italian cohort only included patients that had pro-
gressed, while patients from other countries included
all-comers (progressors and non-progressors).
Results
A total of 362 FAP-OLT patients were preliminarily
assessed from: Portugal, 67; Spain, 59; Sweden, 29;
France, 200; Italy, 7. Patients from Portugal, Spain, and
Sweden all had the Val30Met (V30M) TTR variant,
whereas 69% and 14% of patients from France and Italy
had the V30M TTR variant, respectively. Among all-
comers with a pre-OLT PND score (n=322/355), 61%
underwent transplantation at PND stage of 0 or I, 26%
at stage II, 12% at stage IIIa or IIIb, and <1% at stage
IV. Within the Italian cohort, 43% underwent transplan-
tation at stage I, 43% at stage II and 14% at stage IIIb.
Following OLT, 33% of all-comers (n=107/322) experi-
enced a PND progression; the percent of patients who
progressed varied by country (Sweden, 31%; Portugal,
21%; Spain, 37%; France, 37%). Overall, median time
from transplantation to PND progression, was 2.9 years
(range: 2.5-4.5 years); median time to progression within
the individual countries included: Portugal, 4.5 yrs; Spain,
2.6 yrs; Sweden, 4.0 yrs; France, 2.5 yrs; Italy, 3.0 yrs.
Conclusions
These preliminary data suggest that despite receiving an
OLT, disease progression may not be halted in some
patients with FAP. Based on this multi-national popula-
tion of FAP-OLT patients with both V30M and non-
V30M TTR genotypes, clinically meaningful neuropathy
progression was observed in a median of 2.9 years after
OLT. These findings suggest the need to carefully moni-
tor FAP-OLT patients for signs of progression.
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